Ulcerative Colitis

A greater proportion of patients treated with Tremfya for moderate to severe ulcerative colitis achieved clinical remission at 12 weeks compared with placebo, according to Axel Dignass, MD, PhD, presenting author of a clinical study.

A machine learning model using the endoscopic Mayo Score was able to distinguish between active and inactive disease in ulcerative colitis, according to results presented at the Congress of the European Crohn’s and Colitis Organization.

Zeposia demonstrated a low incidence of treatment-related cardiac adverse events for patients with ulcerative colitis or multiple sclerosis, according to a presenter at the Congress of the European Crohn’s and Colitis Organization.

Among patients with ulcerative colitis, fecal microbiota transplantation with super donor stool was not superior to autologous stool in inducing remission, according to study results.

Patients with ulcerative colitis treated with Rinvoq 45 mg once daily experienced significant improvement in symptoms “as early as day 1,” according to a presenter at the Congress of the European Crohn’s and Colitis Organization.

Upadacitinib induced sustained improvements in abdominal pain, bowel urgency and fatigue in patients with moderate to severe ulcerative colitis, according to research presented at ECCO.

Among patients with ulcerative colitis, IV vedolizumab safely and effectively treated chronic pouchitis following ileal pouch-anal anastomosis, according to research presented at the Congress of European Crohn’s and Colitis Organization.

The proteomic profile of breast milk of women with inflammatory bowel disease may affect an infant’s microbiome development and fecal calprotectin, according to a presenter at the Congress of the European Crohn’s and Colitis Organization.

Patients with Crohn’s disease who stopped infliximab had a significantly higher risk of relapse vs. those who continued combination therapy, according to results presented at the Congress of the European Crohn’s and Colitis Organization.

In this Healio video series, which focuses on cultural competency in the treatment of inflammatory bowel disease, Sumit Bhatia, MD, said many Indian patients do not accept diagnosis of the disease due to cultural stigmas.